In patients with normal lipid levels, rosuvastatin provides a small reduction in CV events (HOPE-3)
In older adults with at least one cardiovascular risk factor but no known cardiovascular
disease, does rosuvastatin 10 mg reduce the likelihood of adverse cardiovascular events?
In patients with a mean initial low-density lipoprotein (LDL) cholesterol level of 128 mg/dL (3.31 mmol/L), rosuvastatin 10 mg once daily provides a small reduction in a composite outcome of cardiovascular (CV) death, nonfatal myocardial infarction, and
nonfatal stroke (number needed to treat [NNT] = 91 over 5.6 years). There is no mortality benefit, though. There is no reason to think that any statin at an equivalent dose wouldn’t have the same benefit. (LOE = 1b)
Yusuf S, Bosch J, Dagenais G, et al, for the HOPE-3
Investigators. Cholesterol lowering in intermediate-risk persons without
cardiovascular disease. N Engl J Med 2016;374(21):2021-2031.